Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

Optimizing Antifibrotic Therapy with Low-Dose Pirfenidone Plus Nintedanib versus High-Dose Pirfenidone or Nintedanib Monotherapy in Idiopathic Pulmonary Fibrosis (OPTIMA-IPF Study): A 36-Month Single-Centre Comparative Study
Дата публикации: 10-08-2026 09:36:01

An article created on 2026-08-10 09:36:01

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Treatable Traits in Interstitial Lung Disease (TTRILD) protocol paper: A randomised controlled trial comparing the targeted management of treatable traits versus standard practice011.8810-08-2026
2Performance of PI-FAB and TARGET scoring systems in post focal therapy mpMRI surveillance020.5310-08-2026
3A Multi-omics Analysis of Lung Tissue to Determine an Appropriate Sensitization Concentration in an Ovalbumin-Induced Allergic Rhinitis Mouse Model019.510-08-2026
4Evaluation of the Relationship between Carcinoma-Associated Fibroblasts and Cancer Stem Cells in Oropharyngeal Squamous Cell Carcinoma019.0910-08-2026
5Direct Coronary Vascular and Lipidomic Remodeling by Low-Dose GLP-1 Agonist Therapy in Cardiometabolic HFpEF02011-08-2026
6Parkinson's Disease Drug Dose Optimization Using Multi-Objective Reinforcement Learning023.3311-08-2026
7Early and Long-Term Clinical Outcomes of Coronary Artery Bypass Grafting in Patients with Heart Failure and Reduced Ejection Fraction: A Cross-Sectional Study019.6310-08-2026
8Polyphenols as multi-target anti-fibrotic agents in oral submucous fibrosis: a scoping review0514-07-2026
9Platinum-Based Chemotherapies-Induced Nephrotoxicity: A Retrospective Analysis of Frequency, Clinical Characteristics, and Outcomes026.6710-08-2026
10Prediction of Multidimensional Post-Translational Modification Profiles in Idiopathic Pulmonary Fibrosis Based on Substrate Availability via Non-Targeted Metabolomics0515-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 22.73. Источник: www.researchsquare.com.